Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
The Mucormycosis is previously named as zygomycosis which is a rare but serious angio-invasive infection which is caused because of group of fungi called as mucormycetes. Spores of these ubiquitous fungi are generally found in soil, fallen leaves, compost, animal dung and air it can be inhaled and then infect the lungs, sinuses and extend into the brain and eyes. Less often, infection may develop when the spores enter the body through a cut or an open wound. It is not a contagious disease i.e. it cannot spread from one person to another. Mucormycosis is an aggressive, life-threatening infection requiring quick diagnosis and early treatment.
The Mucormycosis market is anticipated to grow at CAGR of 7.85% during forecast period of 2021 to 2027. Mucormycosis primarily affects the peoples which are immunocompromised or patient infected with other diseases. The major factors such as increasing prevalence of fungal infection is propelling growth of mucormycosis market. The rising incidences of immunological diseases is also boosting growth of mucormycosis market. However, side effects of drugs is hindering the growth of mucormycosis market during the forecast period of 2021 to 2027.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the mucormycosis market. In addition, complete analysis of changes on mucormycosis expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe.
The mucormycosis market is segmented into the species, diagnosis method, drugs, distribution channel and geography.
The mucormycosis market is comprised of fungal species such as rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other. In which mucor is estimated to dominate the market in 2020. The rising incidences of immunosuppressant diseases is boosting growth of mucormycosis market. High usage of steroid in treatment of COVID-19 patients is also boosting growth of mucormycosis market.
The mucormycosis market is comprised of diagnosis methods such as magnetic resonance imaging, computed tomography, tissue biopsy and others. The computed tomography is estimated to dominate the market in 2020. The rising prevalence of fungal diseases is propelling growth of mucormycosis market. The rising cases of COVID-19 is also boosting growth of mucormycosis market. The rising technological advancement for diagnosis of various diseases is also refuelling growth of mucormycosis market.
The mucormycosis market is comprised of drug types such as Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. In which amphotericin B is estimated to dominate the market in 2020. The amphotericin B are the only licensed drug antifungal therapy which is used as standard of care. However, the L- Amphotericin B is having side effects of renal toxicity.
The mucormycosis market is comprised of distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies. In which hospital pharmacies are anticipated to dominate the market in 2020. The rising patient footfall is propelling growth of mucormycosis market. The high rate of admission in hospital for treatment is also boosting growth of mucormycosis market. The growing number of hospitals is also driving growth of mucormycosis market.
The mucormycosis market is studied for key regions such as North America, Europe, Asia Pacific and Rest of the World. In which North America is anticipated to dominate the market in 2020. The high patient population is propelling growth of mucormycosis market. The well-developed healthcare infrastructure is also boosting growth of mucormycosis market. The growing percentage of diabetes is also driving growth of mucormycosis market.
The major key players such as Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums And Vaccines, Bdr Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited and Tlc Pharma Labs among others.
June 2021: Celon Laboratories launched an alternative drug, Amphotericin B Emulsion for the treatment of mucormycosis.
May 2021: TLC Pharma, a clinical-stage specialty pharmaceutical company, received approval for the New Drug Application (NDA) for Amphotericin B liposome injection (AmphoTLC), form the Central Drugs Standard Control Organization (CDSCO) of India. The drug can be used in the treatment of fungal infections including mucormycosis infections.
2020: Pfizer Inc. in association with its partner Basilea Pharmaceutica Ltd., launched Cresemba (isavuconazole). The drug is used in mucormycosis and invasive aspergillosis.
September 2019: U.S. FDA granted Fast Track designations for intravenous (IV) and oral formulations for fosmanogepix (APX001) developed, by Amplyx Pharmaceuticals.
The report analyses the mucormycosis market based on species, diagnosis method, drugs, distribution channel and geography. Various species of fungi covered in mucormycosis market are rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other. By diagnosis method, the market is segmented into the magnetic resonance imaging, computed tomography, tissue biopsy and other. Based on drugs the market is segmented into Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. Based on distribution channel, the market is segmented into the hospital pharmacies, retail pharmacies and online pharmacies. The report also analyses the impact of COVID-19 on the market and it concludes that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe. The report also comprised of major key players operating in the market.
Why to buy this report
